Comparison · NCT03138733-sae
Ceftobiprole vs Daptomycin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ceftobiprole vs Daptomycin: serious adverse events. Trial comparisons, record NCT03138733-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03138733-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.188 | 0.139 | 0.25 | wilson | |
| Risk in group 2 | 0.227 | 0.174 | 0.291 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0388 | -0.119 | 0.0422 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.829 | 0.561 | 1.23 | log | |
| Odds ratio, group 1 over group 2 | 0.79 | 0.483 | 1.29 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ceftobiprole than on Daptomycin | 25.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ceftobiprole | Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril)~Ceftobiprole: Ceftobiprole 500 mg as a 2 h infusion | 36 | 191 | EG000 |
| Group 2 | Daptomycin | Daptomycin 6 mg/kg, with or without aztreonam~Daptomycin: Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam | 45 | 198 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All AEs occurring from the start of first dosing up to and including the scheduled PTE visit on Day 70 (± 5 days) were collected.
Source ClinicalTrials.gov
Trial
- Title
- Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
- NCT number
- NCT03138733
- Phases
- PHASE3
- Conditions
- Staphylococcus Aureus Bacteremia
- Interventions
- Ceftobiprole medocaril, Daptomycin
- Lead sponsor
- Basilea Pharmaceutica
- Results first posted
- 2023-05-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03138733?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03138733-sae